IO Biotech/IOBT

$1.48

0.68%
-
1D1W1MYTD1YMAX

About IO Biotech

IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.

Ticker

IOBT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Mai-Britt Zocca

Employees

68

Headquarters

Copenhagen, Denmark

IO Biotech Metrics

BasicAdvanced
$98.82M
Market cap
-
P/E ratio
-$2.15
EPS
-
Beta
-
Dividend rate
$98.82M
$2.64
$0.82
135.79K
9.369
-56.91%
-63.29%
-62.35%
0.742
0.742
13.12%

What the Analysts think about IO Biotech

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
440.54% upside
High $10.00
Low $5.00
$1.48
Current price
$8.00
Average price target

IO Biotech Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-26.1M
20.83%
Profit margin
0%
-

IO Biotech Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 3.09%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.59
-$0.74
-$0.43
-$0.40
-
Expected
-$0.71
-$0.66
-$0.44
-$0.39
-$0.36
Surprise
-16.31%
12.12%
-3.15%
3.09%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for IO Biotech stock?

IO Biotech (IOBT) has a market cap of $98.82M as of April 20, 2024.

What is the P/E ratio for IO Biotech stock?

The price to earnings (P/E) ratio for IO Biotech (IOBT) stock is 0 as of April 20, 2024.

Does IO Biotech stock pay dividends?

No, IO Biotech (IOBT) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next IO Biotech dividend payment date?

IO Biotech (IOBT) stock does not pay dividends to its shareholders.

What is the beta indicator for IO Biotech?

IO Biotech (IOBT) does not currently have a Beta indicator.

What is the IO Biotech stock price target?

The target price for IO Biotech (IOBT) stock is $8, which is 440.54% above the current price of $1.48. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell IO Biotech stock

Buy or sell IO Biotech stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing